Studies on the Alternative Pathway in Systemic Lupus Erythematosus Using Rabbit Red Blood Cells
Hiroto Miyashima
Abstract
Open-access reader
Hiroto Miyashima
Abstract
Open-access reader
Methods of measuring the activity of the total alternative complement pathway, properdin and Factor B with rabbit red blood cells(RaRBC) were examined. The following results were obtained.1) 0.03M EGTA-GVB permitted activation of the alternative complement pathway without activation of the classical complement pathway.2) RaRBC were hemolysed by C4/C2 depleted serum as well as by normal serum. RaRBC were not hemolysed by inulin or zymosan treated serum.3) The activity of the total alternative complement pathway was measured with 50% hemolysis of RaRBC in EGTA-GVB, designated as ACH50.4) The activity of properdin or Factor B was measured with RaRBC and normal fresh human serum deficient in properdin(RP) or deficient in Factor B(RB).
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Methods of measuring the activity of the total alternative complement pathway, properdin and Factor B with rabbit red blood cells(RaRBC) were examined. The following results were obtained.1) 0.03M EGTA-GVB permitted activation of the alternative complement pathway without activation of the classical complement pathway.2) RaRBC were hemolysed by C4/C2 depleted serum as well as by normal serum. RaRBC were not hemolysed by inulin or zymosan treated serum.3) The activity of the total alternative complement pathway was measured with 50% hemolysis of RaRBC in EGTA-GVB, designated as ACH50.4) The activity of properdin or Factor B was measured with RaRBC and normal fresh human serum deficient in properdin(RP) or deficient in Factor B(RB).
Key concepts: Properdin, Alternative complement pathway, Classical complement pathway, Complement system, Zymosan, EGTA, Hemolysis, Complement factor B